IRIDEX Corporation — FY2020 Form 10-K
Reporting period: Fiscal year ended January 2, 2021 (53 weeks), compared with the 52-week fiscal year ended December 28, 2019. This is an annual filing, not a standalone fourth-quarter report. IRIDEX develops and sells ophthalmic laser systems, delivery devices, probes and related services for glaucoma and retinal diseases.
Financial results and liquidity
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $36.3 million | $43.4 million | Down 16.3% |
| Gross profit / margin | $15.6 million / 42.8% | $17.9 million / 41.3% | Profit down 13.3%; margin up 1.5 percentage points |
| Operating expenses | $22.1 million | $26.9 million | Down $4.8 million |
| Operating loss | $6.6 million | $9.0 million | Loss narrowed |
| Net loss | $6.3 million; $0.46 per share | $8.8 million; $0.64 per share | Loss narrowed |
| Cash used in operations | $3.2 million | $7.9 million | Cash burn decreased |
| Cash and cash equivalents at year-end | $11.6 million | $12.7 million | Down $1.0 million |
| Working capital at year-end | $16.7 million | $20.8 million | Down $4.1 million |
Revenue declined across product categories: G6 revenue was $11.3 million (down 13.7%), retina revenue was $18.1 million (down 20.9%), and other revenue was $7.0 million (down 6.8%). International sales were $17.0 million, or 46.9% of revenue. The filing attributes the decline principally to COVID-19-related reductions in elective procedures and delays in customer capital purchases. Gross margin improved mainly due to geographic and product mix, partly offset by fixed manufacturing overhead spread across lower volume.
IRIDEX reported a $2.5 million Paycheck Protection Program (PPP) loan, with $1.25 million classified as current and $1.25 million as long-term at year-end. The loan carries 1% interest; the company had applied for full forgiveness but could not assure forgiveness. No amounts were outstanding under its separate revolving credit facility. The company had an accumulated deficit of $56.9 million and stated that it expected operating losses and negative operating cash flow at least through January 1, 2022, while believing available cash would cover anticipated needs for the next 12 months.
Material changes, outlook and notable items
- COVID-19: The pandemic affected procedure volumes, sales, manufacturing capacity, travel and research activity; management expected operating results to remain affected while the pandemic continued. No numerical revenue or earnings guidance was provided.
- Cost actions: Research and development, sales and marketing, and general and administrative expenses declined, primarily reflecting lower personnel costs and, for sales and marketing, lower commissions, travel and marketing activity. Management expected to maintain reduced headcount and lower costs for the foreseeable future.
- Topcon transactions after year-end: On March 2, 2021, IRIDEX agreed to acquire substantially all assets of Topcon Medical Laser Systems, including the PASCAL product, and entered a distribution agreement giving Topcon exclusive rights for IRIDEX glaucoma and retina products in certain territories outside the U.S. Topcon America also purchased 1,618,122 IRIDEX shares for $10 million. The asset acquisition closed March 10, 2021; the filing reports net proceeds of $9.5 million from the transactions. The share issuance is dilutive, and distribution results depend on Topcon’s performance and existing distributor transitions.
- Other commitments and contingencies: Purchase commitments were $9.2 million for fiscal 2021. The Mountain View facility lease was scheduled to expire in February 2022. The company disclosed no material pending legal proceedings. The voluntary recall of the TruFocus LIO Premiere remained subject to a pending FDA termination request; the updated device may still present risks.
- Financial reporting: The auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective as of January 2, 2021; the auditor did not provide an internal-control attestation. Inventory valuation was identified as a critical audit matter due to judgment involved in estimating excess and obsolete inventory.
Key investor verification points
- Track elective ophthalmic procedure volumes, hospital capital spending and the pace of revenue recovery following COVID-19 disruptions.
- Confirm the outcome and any repayment obligations associated with the $2.5 million PPP loan and forgiveness application.
- Assess execution of the Topcon distribution agreement, PASCAL integration, sales baselines, distributor transitions and dilution from the 1,618,122-share issuance.
- Monitor cash burn, working capital, inventory valuation and the company’s ability to fund operations as it continues to report losses.
- Check the status of the TruFocus LIO recall termination request and any additional product-safety or regulatory developments.